Navigation Links
MannKind Corporation Reports First Quarter Financial Results
Date:5/5/2008

cessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

(Tables to follow)

MannKind Corporation

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended March 31,

2008 2007

Revenue $20 $10

Operating expenses:

Research and development 58,445 63,788

General and administrative 15,640 13,550

Total operating expenses 74,085
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... Aug. 26, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... entity wholly owned by Mr. Yuen Kam, chairman of ... the outstanding shares (the "Shares") of  Excellent China Healthcare ...
(Date:8/26/2015)... ... , ... PRC Clinical, a Clinical Trial Management Expert CRO, will ... southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors ... , Stem Cell Meeting on the Mesa on October 7-9 ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... 29 Pharmion Corporation,(Nasdaq: PHRM ) today ... has granted Fast Track designation for oral Azacitidine ... Track programs are designed to facilitate the development ... intended to treat serious or,life-threatening conditions and that ...
... with an overview of cardiovascular genetics ... ... 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... virtually any disease or medical,condition, today announced that its co-founder ...
... Aug. 29 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today announced ... has given clearance to begin marketing the,Hemo-Stream(TM) ... developed by Rex Medical, LP, is the ...
Cached Biology Technology:Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University of Bergen, Norway have deduced how bony fishes ... filling their eggs with the water of life ?the ... genes causes the eggs to fill with vital water ... extant marine teleosts that showed an unprecedented radiation during ...
... Scientists at the MIT Media Lab have invented a ... yellow light, offering the prospect of controlling the haywire ... and Parkinson's disease. , Such diseases often must be ... MIT research could lead to the development of optical ...
... , professor of molecular biophysics and biochemistry at ... Foundation to expand research on the delivery of a targeted ... and his collaborator Zhiwei Hu have developed a way to ... thus destroying the tumors while leaving normal tissue unharmed. ...
Cached Biology News:How fish conquered the ocean 2How fish conquered the ocean 3MIT: Pulsing light silences overactive neurons 2Nanoparticles for delivery of prostate cancer treatment 2
...
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for BrdU in cells and tissues...
Biology Products: